Lightstone Ventures is a global venture capital firm founded in 2012, focusing on biotech and medtech companies that are pioneering transformative therapies and technologies. The firm typically invests in Series A through Series E rounds, with a strong emphasis on translating novel scientific breakthroughs into clinically and commercially meaningful outcomes. Lightstone Ventures partners with visionary entrepreneurs to provide the necessary resources and operational guidance to bring innovative therapeutics to market.
Notable portfolio companies include Nimbus Therapeutics, which has raised $443 million, Earlens with $234 million, and Relievant Medsystems with $178 million. Key partners at Lightstone Ventures include Hong I. Wan, Karun D. Naga from The Foundry, LLC, Susan Molineaux of Calithera Biosciences, Adam D. Gridley from Allay Therapeutics, and Jaume Pons of ALX Oncology. The firm prides itself on being partners, collaborators, and mentors, offering a broad commitment to improving patient outcomes through disruptive technologies.
Lightstone Ventures - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Top Investment Stages
Global venture capital firm, Lightstone Ventures, invests in biotech and medtech pioneers, transforming patient outcomes since 2012.
Stage Mix
Concentration shown as share of disclosed investments by stage.
Lightchain Capital
Lightspeed Venture Partners
lsvp.com
Longitude Capital
Lightrock
lightrock.com
Bioluminescence Ventures
Northern Light Venture Capital
nlvc.com
MedScience Ventures
Starlight Ventures
starlight.vc
Northstar Ventures
Light Street Capital
lightstreet.com
Brightstone Venture Capital
brightstonevc.com
Luminous Ventures
luminous.vc
Lightbank
lightbank.com
BlueStone Venture Partners
bluestonevp.com
Twilight Venture Partners
